ASCO对加拿大安大略癌症治疗中心前列腺癌骨健康与骨靶向治疗指南的认可
ASCO专家小组对加拿大安大略癌症治疗中心(CCO)2017年发布的前列腺癌骨健康与骨靶向治疗指南进行方法学严谨性审查和内容评议,认为推荐意见清晰、全面且基于最相关科学证据,完全认可原指南全部推荐,并提供讨论要点指导临床实践。
要点
- ASCO完全认可CCO前列腺癌骨健康与骨靶向治疗指南的全部推荐。
- 指南覆盖非转移性前列腺癌骨质疏松骨折风险管理至转移性去势抵抗性前列腺癌骨管理。
- ASCO专家小组提供讨论要点以指导临床医生管理骨相关风险。
核心结论
- ASCO专家小组认定CCO前列腺癌骨健康与骨靶向治疗指南推荐清晰、全面且基于最相关科学证据,ASCO完全认可该指南。
研究设计与样本
- ASCO采用其认可其他专业组织制定的临床实践指南的政策和程序,由方法学家审查指南开发严谨性,再由ASCO专家小组评议内容和推荐。
主要发现
- ASCO专家小组认定CCO指南推荐清晰、全面且基于最相关科学证据,ASCO完全认可该指南。
关键数值与推荐
- ASCO专家小组按原文认可全部原指南推荐,并提供系列讨论要点以指导临床医生管理该患者人群的骨相关风险。
临床怎么用
- 临床医生可依据ASCO认可的CCO指南管理前列腺癌患者骨健康与骨靶向治疗,并参考ASCO讨论要点指导骨相关风险管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In 2017, Cancer Care Ontario's Program in Evidence-Based Care released the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline. This guideline included recommendations across a relatively broad clinical spectrum within prostate cancer. Topics addressed ranged from management of osteoporotic fracture risk in nonmetastatic disease to management of men with castration-resistant prostate cancer metastatic to bone. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS: The Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline was reviewed for developmental rigor by methodologists. An ASCO Expert Panel then reviewed the content and the recommendations. RESULTS: The ASCO Expert Panel determined that the recommendations from the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline were clear, thorough, and based on the most relevant scientific evidence. ASCO wholly endorses the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline. RECOMMENDATIONS: The ASCO Expert Panel endorses all the original guideline recommendations as written and offers a series of discussion points to guide practice for clinicians as they manage bone-related risks within this patient population.
引用
- Saylor PJ, Rumble RB, Tagawa S, et al. Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. J Clin Oncol. 2020. PMID: 31990618. doi:10.1200/JCO.19.03148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。